Home / Business and Economy / Roche's Drugs Show Promising Results in Crucial Trials
Roche's Drugs Show Promising Results in Crucial Trials
11 Nov
Summary
- Roche's fenebrutinib and giredestrant drugs show better-than-expected trial results
- Deutsche Bank upgrades Roche stock from sell to hold
- Target price on Roche stock raised to 265 Swiss francs
On November 9, 2025, Roche's fenebrutinib and giredestrant drugs have shown better-than-expected results in crucial trials, according to a note from Deutsche Bank analyst Emmanuel Papadakis. This has led the analyst to upgrade Roche's stock recommendation from sell to hold.
Papadakis states that while the "partial success" of the fenebrutinib results in multiple sclerosis does not single-handedly resolve all of Roche's challenges, it is enough to shift the analyst's "outright caution to a more neutral perspective." As a result, the discount compared to Roche's European pharmaceutical peers is no longer necessary, and the target price on the stock has been raised from 235 Swiss francs to 265 Swiss francs.
The improved outlook for Roche's drug pipeline is a positive development for the company, which has faced some headwinds in recent years. The successful trials of fenebrutinib and giredestrant suggest that Roche's research and development efforts are bearing fruit, and could help the company maintain its position as a leading player in the pharmaceutical industry.
